Researchers conducted a phase 2B clinical trial that included adult patients with two or more C. diff recurrences. The patients were randomized to receive:
• Two doses of RBX2660 — Group A
• Two doses of placebo — Group B
• One dose of RBX2660 followed by one dose of placebo — Group C
The researchers defined efficacy as prevention of recurrent C. diff for eight weeks following treatment.
The overall efficacy for participants treated with RBX2660 was 88.8 percent.
The study shows the drug efficacy for the groups were as follows:
• Group A: 61 percent
• Group B: 45 percent
• Group C: 67 percent.
Thus, one dose of RBX2660 was found to be superior to placebo. Additionally, the proportion of adverse or serious adverse events did not differ significantly between the groups.
More articles on healthcare quality:
32 latest findings on C. diff
Can leadership rounds reduce HAIs?
Top 10 infection control, patient safety stories for March
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
